Therapeutic activity of an interleukin-4/interleukin-13 dual antagonist on oxazolone-induced colitis in mice

Related Experiment Video

Updated: Apr 29, 2026

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

12.3K

Marion T Kasaian1, Karen M Page, Susan Fish

  • 1Immunoscience, Pfizer, Cambridge, MA, USA.

Immunology
|May 17, 2014
PubMed

Insights

Dual targeting of Interleukin-4 (IL-4) and IL-13 with a novel bifunctional therapeutic effectively reduced inflammation and disease severity in a preclinical model of ulcerative colitis.

Area of Science:

  • Immunology
  • Gastroenterology
  • Pharmacology

Background:

  • Interleukin-4 (IL-4) and Interleukin-13 (IL-13) are key cytokines driving immune responses and inflammation in diseases like ulcerative colitis and asthma.
  • Their overlapping functions suggest that dual blockade may offer superior therapeutic efficacy compared to targeting either cytokine alone.

Purpose of the Study:

  • To evaluate the efficacy of a novel bifunctional therapeutic agent designed to simultaneously antagonize both IL-4 and IL-13.
  • To assess the therapeutic potential of this dual-targeting approach in a preclinical model exhibiting features of ulcerative colitis.

Main Methods:

  • The study utilized the oxazolone-induced colitis model in mice to mimic ulcerative colitis.
  • The bifunctional IL-4/IL-13 antagonist was administered, and its effects on disease parameters were measured over a 7-day period.
  • Biomarkers including body weight, colon weight, colon length, colon tissue gene expression, and serum amyloid P concentrations were analyzed.

Main Results:

  • The bifunctional IL-4/IL-13 antagonist significantly reduced body weight loss, colon weight increase, and colon length decrease associated with colitis.
  • Treatment modulated colon tissue gene expression, indicating an anti-inflammatory effect.
  • Serum amyloid P levels correlated with disease severity and were inversely related to the antagonist's serum concentration, serving as a potential biomarker.
  • The antagonist's serum levels were inversely proportional to disease severity, pro-inflammatory gene expression, and serum amyloid P.

Conclusions:

  • The study demonstrates the therapeutic effectiveness of a bifunctional IL-4/IL-13 antagonist in a preclinical model of ulcerative colitis.
  • The findings validate the role of the IL-4/IL-13 pathway in this model and highlight the utility of identified biomarkers for assessing treatment response.
  • Dual blockade of IL-4 and IL-13 presents a promising strategy for managing inflammatory conditions like ulcerative colitis.
Keywords:
bifunctionalcolitiscytokine

More Related Videos

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.9K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.6K

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
701
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
753
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
33
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
691
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
876